Current and next generation influenza vaccines: Formulation and production strategies
Top Cited Papers
Open Access
- 1 August 2015
- journal article
- review article
- Published by Elsevier BV in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 94, 251-263
- https://doi.org/10.1016/j.ejpb.2015.05.023
Abstract
No abstract availableKeywords
Funding Information
- Center for Translational Molecular Medicine
This publication has 100 references indexed in Scilit:
- Engineering of papaya mosaic virus (PapMV) nanoparticles with a CTL epitope derived from influenza NPJournal of Nanobiotechnology, 2013
- The unmet need in the elderly: How immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccinesVaccine, 2012
- Recombinant protein vaccines produced in insect cellsVaccine, 2012
- Trivalent and quadrivalent MF59®-adjuvanted influenza vaccine in young children: A dose- and schedule-finding studyVaccine, 2011
- Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferretsVaccine, 2011
- Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of ageVaccine, 2011
- MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivationApplied Microbiology and Biotechnology, 2010
- Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturingVaccine, 2010
- Development of Stable Influenza Vaccine Powder Formulations: Challenges and PossibilitiesPharmaceutical Research, 2008
- Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvantVaccine, 2007